Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

United Therapeutics’ Tyvaso DPI Approved for Rare High Blood Pressure Disease

United Therapeutics’ Tyvaso DPI Approved for Rare High Blood Pressure Disease

The FDA has approved United Therapeutics’ Tyvaso DPI (trepostinil) in an inhaled powder formulation  for patients with pulmonary arterial hypertension, a rare type of high blood pressure disease that affects arteries in the lungs and heart.

The approval was supported by positive results from a clinical trial that transitioned 51 participants from the inhalation solution to Tyvaso DPI. The powder formulation led to significant improvements in patients’ six-minute walk distance and reported outcomes, the company said.

The FDA approved Tyvaso inhalation solution for treatment of pulmonary arterial hypertension in April 28, 2009. The new formulation delivers “the proven efficacy of treprostinil through a small inhaler that fits in the palm of the patient’s hand,” said Michael Benkowitz, the company’s chief operating officer.

May 27, 2022


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies